Jeremy Schreiber

MSN, PMHNP-BC

Founder, CEO, and Psychiatric-Mental Health Nurse Practitioner Prescriber, Enlighten Health Care

Jeremy Schreiber,

MSN, PMHNP-BC

Founder, CEO, and Psychiatric-Mental Health Nurse Practitioner Prescriber, Enlighten Health Care

Jeremy's Shared Resources

Link Between Antidepressants and Tardive Dyskinesia Explored

In a recent study, researchers critiqued various reviews and case reports associating non-dopamine-receptor-blocking drugs (DRBDs) with a tardive dyskinesia (TD) like syndrome, examining if the cases met TD criteria and

Researchers Examine Effectiveness of VMAT2 Inhibitors in Treating Tardive Dyskinesia

Researchers of a study examined the effectiveness of vesicular monoamine transporter-2 (VMAT2) inhibitors and other agents in light of different theories regarding the development of tardive dyskinesia (TD). Researchers found

Understanding Tardive Dyskinesia

The author of this article gives an overview of tardive dyskinesia (TD). TD can potentially be a permanent movement disorder that is caused by dopamine receptor blocking agents (DRBAs) in

CURATED BY:
Jeremy Schreiber

Authors Review Impact of Calcium Channel Blockers on Antipsychotic-Induced Tardive Dyskinesia

Authors of a review looked to study the impact of calcium channel blocker therapies (diltiazem, nifedipine, nimodipine, verapamil) in treating patients with neuroleptic-induced tardive dyskinesia (TD) and chronic mental illnesses

CURATED BY:
Jeremy Schreiber

Exploring the Dopamine-Based Pathophysiology of Tardive Dyskinesia

The leading theory on the pathophysiology of tardive dyskinesia (TD) is that chronic treatment with dopamine receptor-blocking agents (DRBAs) causes a “supersensitivity” of dopamine receptors in the dorsal striatum. Researchers

CURATED BY:
Jeremy Schreiber

Insights on Treating Tardive Dyskinesia Using Telehealth

A panel of six neurologists, three psychiatrists, and three psychiatric nurse practitioners participated in a study to outline a framework to address the use of telehealth to treat tardive dyskinesia.

CURATED BY:
Jeremy Schreiber